|
Re: Eligibility for registered accounts in Canada
|
2
|
Zenith Epigenetics
|
Aug 18, 2018 12:21PM
|
|
Re: Orphan Disease Announcement
|
2
|
Resverlogix Corp.
|
Sep 24, 2015 08:13PM
|
|
Re: Clinical Trials
|
2
|
BIOASIS TECHNOLOGIES INC
|
Feb 04, 2017 07:08PM
|
|
Re: Question re BOD votes
|
2
|
Resverlogix Corp.
|
Jun 27, 2022 10:26AM
|
|
Re: CRISPR vs. BET inhibitors
|
2
|
Resverlogix Corp.
|
Jan 10, 2016 11:10PM
|
|
Re: Additional Reports Of Exempt Distribution.
|
2
|
Zenith Epigenetics
|
Jun 07, 2024 11:10AM
|
|
Re: PNH
|
2
|
Resverlogix Corp.
|
Sep 24, 2015 10:01PM
|
|
Re: Bioasis Announces Private Placement and Intention to Pursue NASDAQ Listing
|
2
|
BIOASIS TECHNOLOGIES INC
|
May 14, 2018 12:18PM
|
|
Re: Adjudication
|
2
|
Resverlogix Corp.
|
Dec 28, 2018 11:02PM
|
|
Re: Apabetalone inhibits kidney damage in diabetes
|
2
|
Resverlogix Corp.
|
Aug 21, 2024 11:45AM
|
|
Re: Looking over Amarin does lead to one obvious conclusion...
|
2
|
Resverlogix Corp.
|
Feb 14, 2019 02:00PM
|
|
New exempt distribution
|
2
|
Resverlogix Corp.
|
May 05, 2021 07:58PM
|
|
Re: Clarification received...
|
2
|
Resverlogix Corp.
|
Jun 08, 2018 06:46PM
|
|
Re: Still waiting for a sufficient answer
|
2
|
Resverlogix Corp.
|
May 19, 2018 10:25AM
|
|
Re: a new study that one researcher called "stunning."
|
2
|
Resverlogix Corp.
|
Feb 11, 2022 10:39AM
|
|
Re: The Prescription....Nove... 15th
|
2
|
Resverlogix Corp.
|
Nov 17, 2017 01:24PM
|
|
Re: Resverlogix Announces Successful Phase 1 Renal Trial Results...
|
2
|
Resverlogix Corp.
|
Nov 17, 2016 10:42AM
|
|
Re: Resverlogix Announces Successful Phase 1 Renal Trial Results...
|
2
|
Resverlogix Corp.
|
Nov 17, 2016 10:47AM
|
|
Re: Another trade for Koo
|
2
|
Resverlogix Corp.
|
Jun 21, 2017 08:52PM
|
|
Re: Contest Tally
|
2
|
Resverlogix Corp.
|
Feb 13, 2019 10:31AM
|
